Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | MAOA | P21397 | 3/20 | 0.35 |
| ▸ | MAOB | P27338 | 3/20 | 0.35 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | HTR2C | P28335 | 1/20 | 0.32 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.32 |
| ▸ | NOS3 | P29474 | 1/20 | 0.31 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.31 |
| ▸ | BAD | Q92934 | 1/20 | 0.31 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.31 |
| ▸ | IDO1 | P14902 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30165716 | 0.91 | TSHR (0.50) | TSHRMAOAMAOBCYP2A6MAPT | |
| SCHEMBL4459017 | 0.86 | TSHR (0.50) | TSHRMAOAMAOBCYP2A6MAPT | |
| SCHEMBL24069533 | 0.69 | — | — | |
| SCHEMBL13371771 | 0.69 | TSHR (0.43) | TSHRMAOAMAOBCYP2A6HTR2C | |
| SCHEMBL19039049 | 0.67 | CES1 (0.45) | MAOAMAOBCYP2A6HPGDL3MBTL1 | |
| SCHEMBL11645158 | 0.67 | TSHR (1.00) | TSHRMAOAMAOBCYP2A6MAPT | |
| SCHEMBL385555 | 0.67 | TSHR (1.00) | TSHRMAOAMAOBCYP2A6MAPT | |
| SCHEMBL451157 | 0.67 | TSHR (0.86) | TSHRMAOAMAOBCYP2A6MAPT | |
| SCHEMBL9662 | 0.67 | — | — | |
| SCHEMBL8355 | 0.67 | TSHR (1.00) | TSHRMAOAMAOBCYP2A6MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4203134-A1 | ELECTROLYTE FOR LITHIUM SECONDARY BATTERY AND LITHIUM SECONDARY BATTERY COMPRISING SAME | LG Energy Solution, Ltd. (KR) | 2023-06-28 | — | — | EP | disclosed |
| WO-2017079867-A1 | POLYMERIZABLE COMPOUND AND OPTICALLY ANISOTROPIC BODY | DIC CORPORATION (JP) | 2017-05-18 | — | — | WO | disclosed |
| US-20090273277-A1 | Novel organic electroluminescent compounds and organic electroluminescent device using the same | GRACEL DISPLAY INC. (KR) | 2009-11-05 | — | — | US | disclosed |
| US-20090273277-A1 | Novel organic electroluminescent compounds and organic electroluminescent device using the same | GRACEL DISPLAY INC. (KR) | 2009-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090273277-A1 | Novel organic electroluminescent compounds and organic electroluminescent device using the same | OCIAD1, ORMDL3, CHRM2 | TSHR 3938/4885MAOA 1037/4885MAOB 891/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.